Venezuela is emerging as an untapped opportunity for medical device and pharmaceutical clinical trials in Latin America. With a 30+ million population, 60,000+ trained physicians, competitive costs, and an ICH-GCP compliant regulatory framework through MPPS and INHRR, bioaccess® is the first CRO to establish clinical trial operations in Venezuela.
Key Takeaways Venezuela is the 3rd largest medical device market in Latin America , after Brazil and Mexico The MPPS/INHRR regulatory framework follows ICH-GCP standards — clinical data is accepted by FDA and EMA Over 60,000 community doctors trained through the MIC program, plus traditional medical school graduates Private hospital sector operates at 100% capacity with modern infrastructure Medical device registration through SACS takes approximately 20 business days bioaccess® is the first CRO to establish clinical trial operations in Venezuela While countries like Colombia, Mexico, and Brazil have long dominated the Latin American clinical research landscape , a new frontier is emerging. Venezuela , with its 30+ million population, highly trained physician workforce, and competitive operational costs, represents one of the most significant untapped opportunities for medical device and pharmaceutical sponsors in the region. bioaccess® is proud to be the first CRO to establish clinic…